Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTI-0102 in MELAS
NCT06644534Phase 2Completed
- Sponsor
- Thiogenesis Therapeutics
- Start
- May 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of cysteamine-pantetheine disulfide in Mitochondrial encephalomyopathy (ME), sponsored by Thiogenesis Therapeutics. Started May 2025; status: completed.
02
Drugs
cysteamine-pantetheine disulfide
03
Conditions
Mitochondrial encephalomyopathy (ME)
Beyond the preview
Go deeper on NCT06644534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06644534.